Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage

pdf downloadData Post Download

The world is in midst of the COVID-19 pandemic. The first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021. This variant has a large number of mutations, some of which are concerning. Preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs. Below is the mutations in the spike:

Picture loading failed.
Figure. Amino acid changes in the spike region of the Omicron variant aka B.1.1.529 lineage genomes1. Note: In our product, N211I→Δ211.

Spike Mutation in SARS-COV-2 (2019nCOV)
Omicron variant aka B.1.1.529 lineage
Spike-S1 Subunit N Terminal A67V
Δ69-70
T95I
G142D
Δ143-145
Δ211-212
ins214EPE
Spike-RBD G339D Important residues mutation
Important residues mutation
S371L
S373P
S375F
K417N
N440K
G446S
S477N
T478K
E484A
Q493R
G496S
Q498R
N501Y
Y505H
Spike-S1 Subunit T547K
D614G A popular mutation in different new
SARS-CoV-2 lineage
H655Y
N679K
P681H
Spike-S1 Subunit N764K
D796Y
N856K
Q954H
N969K
L981F
Table. Amino acid changes in the spike region of the Omicron variant aka B.1.1.529 lineage genomes.

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage


Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.

Cat No. Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants Order
GM-2019nCoV-PSV39 Spike RBD mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (Omicron variant aka B.1.1.529)
production and Pseudovirus Based Neutralization Assay
Picture loading failed.
GM-2019nCoV-PSV40 Spike whole mutant SARS-CoV-2(2019nCoV)Omicron variant aka B.1.1.529 Pseudotyped virus
production and Pseudovirus Based Neutralization Assay
Picture loading failed.

SARS-COV-2 (2019nCOV) Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein) & High-throughput screening (HTS) assay for efficacy evaluation and development of antiviral compounds

Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein) is a target protein of antiviral compounds, which are valid for all SARS-COV-2 (2019nCOV) lineage, including Omicron variant aka B.1.1.529 lineage. The latest research shows that Pfizer’s paxlovid is effective to SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage, based on the inhibition of Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein). Thus, GeneMedi provides SARS-COV-2 (2019nCOV) Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein) & High-throughput screening (HTS) assay for efficacy evaluation and development of antiviral compounds

Cat No. Antigen Name of 2019-nCoV(SARS-CoV-2) Source (Expression Host) Order
GMP-V-2019nCoV-Mpro001Recombinant 2019nCoV antigen-coronavirus Main Proteinase (Mpro, 3CLpro, His Tag)E.coliPicture loading failed.

SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage neutralizing antibody

GeneMedi has quickly screened these three neutralizing antibodies, which are valid for all SARS-COV-2 (2019nCOV) lineage, including Omicron variant aka B.1.1.529 lineage. They could be used as Benchmark Antibody, assist in neutralizing antibody discovery and development.

Cat No. Neutralizing antibody Name Isotypes Order
GMP-V-2019nCoV-SnAb006Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)Mammalian (human cell)Picture loading failed.
GMP-V-2019nCoV-SnAb007Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)Mammalian (human cell)Picture loading failed.
GMP-V-2019nCoV-SnAb008Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)Mammalian (human cell)Picture loading failed.

SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 diagnostic, vaccines and therapeutic antibodies

GeneMedi has quickly designed the Spike Protein RBD, Spike S-trimer Protein and Nucleocapsid protein (NP) for COVID-19 SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage to help accelerate the COVID-19 diagnostic, vaccine and therapeutic antibody discovery and development.

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage

GeneMedi has quickly designed the mammalian expression codon-optimized spike mutation/deletion variant vectors for COVID-19 SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development.

Cat No. Gene & Vector description of 2019 nCoV Vector Tag Codon Optimized Order
GMV-V-2019nCoV-192 pGM-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 pcDNA3.1(+) No tag Codon Optimized for mamamlian Picture loading failed.
GMV-V-2019nCoV-193 Ad-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Pre-made adenovirus C-3FLAG Codon Optimized for mamamlian Picture loading failed.
GMV-V-2019nCoV-194 pGMLV-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Lentiviral vector C-3FLAG Codon Optimized for mamamlian Picture loading failed.
GMV-V-2019nCoV-195 pGM-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 pcDNA3.1(+) No tag Codon Optimized for mamamlian Picture loading failed.
GMV-V-2019nCoV-196 Ad-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Pre-made adenovirus C-3FLAG Codon Optimized for mamamlian Picture loading failed.
GMV-V-2019nCoV-197 pGMLV-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 Lentiviral vector C-3FLAG Codon Optimized for mamamlian Picture loading failed.

Reference

1.https://covdb.stanford.edu/page/mutation-viewer/#omicron



GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy